Search Results

Veristat, the Science-First Full Service CRO and Consultancy, announced it has joined the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization championing the benefits of cell and gene therapies for patients, healthcare systems, and society.

Cryoport, Inc. and Minaris Regenerative Medicine Co., today announced a strategic partnership to provide fully integrated logistics and manufacturing services to biotechnology and pharmaceutical companies for regenerative medicine products to support the advancement of cell and gene therapies.

Aurion Biotech today announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) Designation for AURN001, the Company’s allogeneic cell therapy candidate for the treatment of corneal edema secondary to corneal endothelial disease.

XNK Therapeutics AB announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14.

Senti Biosciences, Inc., a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, announced that the California Institute for Regenerative Medicines has awarded an $8 million grant to Senti Bio.

Humacyte, Inc. has been granted the U.S. Food and Drug Administration’s (FDA’s) Regenerative Medicine Advanced Therapy (RMAT) designation for patients with advanced peripheral artery disease (PAD).

Andelyn Biosciences, Inc. has been selected to manufacture adeno-associated vectors therapies using its suspension AAV Curator™ Platform under the California Institute for Regenerative Medicine Accelerating Medicines Partnership Bespoke Gene Therapy Consortium.

CytoHub, Inc., a pioneering developer of intelligent technologies for cell therapy and regenerative medicine, announced the strategic addition of three top industry experts to its team.

TScan Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to TSC-100 and TSC-101, the Company’s two lead TCR-T therapy candidates for the treatment of heme malignancies.

uniQure N.V. announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation for its investigational gene therapy AMT-130 for the treatment of Huntington’s disease.